Merck
VC Fund
Darmstadt, Germany
Merck (d.b.a. EMD Millipore in the U.S. and Canada) is a German chemical and pharmaceutical company. Merck, also known as “German Merck” and “Merck Darmstadt”, was founded in Darmstadt, Germany, in 1668, making it the world's oldest operating chemical and pharmaceutical company. The company was privately owned until going public in 1995.However, the Merck family still controls a majority (≈70%) of the company's shares.Following World War I, Merck lost possession of its foreign sites, including the Merck & Co. subsidiary in the United States. Merck & Co., which operates as Merck Sharp and Dohme (MSD) outside the U.S. and Canada, is now an independent company.Merck KGaA operates mainly in Europe, Africa, Asia, Oceania and Latin America. Since Merck & Co. holds the rights to the Merck name in the U.S. and Canada, the company operated under the umbrella brand EMD Chemicals in North America, and since 2010 as EMD Millipore (after the acquisition of Millipore Corporation), formed from the initials of Emanuel Merck, Darmstadt.Founded in 1668 in Darmstadt, Merck KGaA of Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The success of the export business to the United States led in 1887 to the establishment of an office in New York, which gave rise to their subsidiary Merck KGaA Subsidiaries:- -
- Total investments:
- 16
- Last investment:
- Lead investor:
- 63%
Last updated:
For AI agents: llms.txt
Industries Merck invests in
Stages Merck invests in
Countries Merck invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 8 contacts → | |||
Round size
- Seed
- $50k–$4.7M
- Grant
- $29k–$60k
- Series A
- $25M–$84M
Investment Focus
Industry
- Biotechnology 12 (75%)
- Pharmaceutical 5 (31%)
- Medical 4 (25%)
- Health Care 4 (25%)
- Life Science 4 (25%)
Stage
- Grant 4 (25%)
- Seed 3 (19%)
- Series A 2 (13%)
- Post-IPO Equity 2 (13%)
- Venture - Series Unknown 2 (13%)
Country
- United States 9 (56%)
- Germany 2 (13%)
- China 1 (6%)
- Sweden 1 (6%)
- Denmark 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andrea Herrmann
Associate Director, Strategy Implementation Leader
|
Associate Director, Strategy Implementation Leader | Total investments: 0 | Find email | |
Anna Lena Fritzsche
Manager People Analytics Consultancy & Organization Development
|
Manager People Analytics Consultancy & Organization Development | Total investments: 0 | Find email | |
Craig Roberts
AVP, Vaccines, Center for Observational and Real-World Evidence
|
AVP, Vaccines, Center for Observational and Real-World Evidence | Total investments: 0 | Find email | |
|
Raymond Behrendt
R&D Manager
|
R&D Manager | Total investments: 0 | Find email | |
Karim Bendhaou
Head of Africa Affairs
|
Head of Africa Affairs | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders. | $25M / Series A / Dec 10, 2024 | ||
Loma Therapeutics
|
Loma Therapeutics is developing targeted immunotherapy for the effective and safe treatment of HPV infection, dysplasia, and cancer patients. | $45K / Grant / Jun 24, 2024 | |
| Proteologix is a precision immunology company powered by proprietary multi-specific antibody technologies. The company is dedicated to the discovery and development of safe and convenient therapeutics that target multiple disease-driving pathways to potentially deliver high-bar efficacy for patients with immune-mediated diseases. | Grant / Jun 06, 2023 | ||
| Eurocine Vaccines creates nasal flu vaccines designed for children and the elderly. They manage all elements of vaccine development, including preclinical and clinical development, scalability into manufacturing, business development, and funding. | $29.3K / Grant / May 04, 2023 | ||
| Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy.Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. | $84M / Series A / Aug 25, 2022 | ||
| Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions. | $221M / Series B / Aug 16, 2022 | ||
| Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a uniquepartnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK. | $30M / Venture - Series Unknown / Dec 03, 2020 | ||
| Formo is Europe’s first cellular agriculture company developing animal-free dairy products using real, nature-identical milk proteins derived from precision fermentation. | $4.7M / Seed / Dec 19, 2019 | ||
| Formo is Europe’s first cellular agriculture company developing animal-free dairy products using real, nature-identical milk proteins derived from precision fermentation. | $4.7M / Seed / Dec 19, 2019 | ||
| Mosaic is a technology company that provides children's precise development and professional rehabilitation services. | $8.8M / Venture - Series Unknown / Jul 17, 2018 | ||
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Merck invest in?
Merck invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Grant and Seed stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Merck's check size?
Merck typically joins rounds of $50k–$4.7M at Seed, $29k–$60k at Grant and $25M–$84M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Merck participates in.
How do I contact Merck?
Public channels for Merck include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Merck?
The team at Merck includes Andrea Herrmann (Associate Director, Strategy Implementation Leader), Anna Lena Fritzsche (Manager People Analytics Consultancy & Organization Development) and Craig Roberts (AVP, Vaccines, Center for Observational and Real-World Evidence), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
